EUVIMEDEUVIMED entdecken
Video/Audio

A 5-Metabolite Plasma Panel Predicts Progression-Free Survival and Adds Prognostic Value in Imatinib-Treated Gastrointestinal Stromal Tumors

Yu Ruixin, Wang Yi, Yu Jun, Zeng Yicong, Cheng Nan, Li Bin

Journal of Visualized Experiments · 2026

DOI: 10.3791/71407 ↗

Kurz gefasst

Video/Audio in der Zeitschrift Journal of Visualized Experiments, 2026. Verfasst von Yu Ruixin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Chongzhou People's Hospital. Hauptthemen laut MEDLINE: Imatinib Mesylate, Gastrointestinal Stromal Tumors, Antineoplastic Agents, Gastrointestinal Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among patients with gastrointestinal stromal tumor receiving first-line imatinib, outcomes vary substantially, and traditional stratification based on KIT/PDGFRA genotype and tumor burden does not fully explain individual prognostic differences. Baseline plasma metabolomics may noninvasively reflect the tumor-host systemic state and provide additional prognostic information. This single-center prospective cohort study aimed to develop and internally validate a baseline plasma-based metabolomic risk score and to assess its incremental discrimination, calibration, and clinical net benefit over a clinical benchmark model. Patients with gastrointestinal stromal tumor receiving first-line imatinib were enrolled from 2019 to 2023 and followed until June 30, 2025. Baseline plasma samples were collected before the first dose of imatinib, and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-derived metabolomic features were processed using quality-control procedures and normalization. An elastic-net penalized Cox model was used to select metabolites and construct the risk score, with 0.632+ bootstrap resampling used for optimism correction, time-dependent receiver operating characteristic analysis for discrimination, calibration analysis, and decision curve analysis for exploratory net-benefit assessment. A total of 200 patients were included, with 5178.64 person-months of follow-up and 104 progression-free survival events. A five-metabolite panel was identified, and in the development cohort, the fitted continuous metabolomic risk score showed an apparent association with progression-free survival. Compared with the clinical benchmark model, the combined model improved the C-index by 0.06 and showed overall higher time-dependent area under the curve (AUC) values over 0-36 months. Calibration at 1 and 2 years was close to the ideal line, and decision curve analysis showed higher model-based net benefit across the evaluated threshold ranges. The baseline five-metabolite plasma panel, therefore, provides incremental prognostic information beyond conventional clinical factors. External validation and prospective impact studies are required before the score can be used to guide clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateGastrointestinal Stromal TumorsAntineoplastic AgentsGastrointestinal NeoplasmsHumansPrognosisProgression-Free SurvivalFemaleMaleProspective StudiesMiddle AgedTandem Mass SpectrometryMetabolomicsAgedLiquid Chromatography-Mass Spectrometry

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Chongzhou People's Hospital.
  • Department of Hepatobiliary Surgery, Chengdu First People's Hospital.
  • Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College.
  • Department of Gastrointestinal Surgery, Chongzhou People's Hospital; cnan33_912@163.com.
  • Department of Gastrointestinal Surgery, Chongzhou People's Hospital; 18180907227@163.com.

Zitieren

APA

Ruixin, Y., Yi, W., Jun, Y., Yicong, Z., Nan, C., & Bin, L. (2026). A 5-Metabolite Plasma Panel Predicts Progression-Free Survival and Adds Prognostic Value in Imatinib-Treated Gastrointestinal Stromal Tumors. Journal of Visualized Experiments. https://doi.org/10.3791/71407

Vancouver

Ruixin Y, Yi W, Jun Y, Yicong Z, Nan C, Bin L. A 5-Metabolite Plasma Panel Predicts Progression-Free Survival and Adds Prognostic Value in Imatinib-Treated Gastrointestinal Stromal Tumors. Journal of Visualized Experiments. 2026. doi:10.3791/71407

BibTeX
@article{Ruixin2026,
  author = {Ruixin, Yu and Yi, Wang and Jun, Yu and Yicong, Zeng and Nan, Cheng and Bin, Li},
  title = {A 5-Metabolite Plasma Panel Predicts Progression-Free Survival and Adds Prognostic Value in Imatinib-Treated Gastrointestinal Stromal Tumors},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/71407}
}
Kostenlos starten →